as on November 15, 2025 at 2:29 am IST
Day's Low
Day's High
1.95%
Downside
1.02%
Upside
52 Week's Low
52 Week's High
7.27%
Downside
34.29%
Upside
Check Biomarin Pharmaceutical Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$10.6B
EPS (TTM)
3.5681
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
1.24%
PE Ratio (TTM)
20.57
Industry PE ratio
19.200384615384614
PEG Ratio
0.6491
EBITDA
794.0M
Revenue (TTM)
3.1B
Profit Margin
16.82%
Return On Equity TTM
9.07%
Track how Biomarin Pharmaceutical Inc. P/E has moved over time to understand its valuation trends.
Biomarin Pharmaceutical Inc. in the last 5 years
Lowest (13.26x)
September 30, 2025
Industry (19.20x)
November 14, 2025
Today (20.57x)
November 14, 2025
Highest (181.43x)
June 30, 2023
Today’s Price to Earnings Ratio: 20.57x
Compare market cap, revenue, PE, and other key metrics of Biomarin Pharmaceutical Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $10.6B | -30.06% | 20.57 | 16.82% | |
| BUY | $59.8B | 235.01% | 1414.81 | 1.36% | |
| NA | $40.9B | NA | 712.21 | 1.38% | |
| BUY | $110.2B | 92.67% | 30.58 | 31.35% | |
| BUY | $71.6B | 22.7% | 16.34 | 32.13% |
The Biomarin Pharmaceutical Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Biomarin Pharmaceutical Inc. investment value today
Current value as on today
₹88,640
Returns
Returns from Biomarin Pharmaceutical Inc. Stock
Dollar Returns*
₹5,194 (+5.19%)
Based on 35 analysts
74.29%
Buy
25.71%
Hold
0.00%
Sell
Based on 35 analysts, 74.29% of analysts recommend a 'BUY' rating for Biomarin Pharmaceutical Inc.. Average target price of $90.5
Get share price movements and forecasts by analysts on Biomarin Pharmaceutical Inc..
What analysts predicted
39.51%UPSIDE
Target Price
$90.5
Current Price
$54.74
Analyzed by
35 Analysts
Target
$90.50
Biomarin Pharmaceutical Inc. target price $90.5, a slight upside of 39.51% compared to current price of $54.74. According to 35 analysts rating.
Search interest for Biomarin Pharmaceutical Inc. Stock has decreased by -5% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 28 October
Tue, 11:01 AM
-BioMarin's Q3 results show 4.1% revenue growth; adjusted EPS guidance lowered by over 20%.
Tue, 06:56 PM
-RBC Capital lowers BioMarin's price target to $66, maintaining a Sector Perform rating after Q3 results.
Tue, 09:40 PM
-BioMarin shares rise 4.5% post-earnings report despite earnings miss; revenue guidance slightly increased.
Today's Timeline - 28 October
Tue, 09:54 PM
-Wells Fargo and Morgan Stanley maintain Buy ratings on BioMarin, citing growth potential and strong market position.
Tue, 11:56 PM
-BioMarin reports Q3 earnings; adjusted EPS of 12 cents beats estimates, but revenues miss expectations.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, BMRN stock has moved up by 5.4%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 77.3% return, outperforming this stock by 114.4%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 94.7% return, outperforming this stock by 109.2%
Profit Down
![]()
Netprofit is down for the last 2 quarters, 240.53M → -30.74M (in $), with an average decrease of 112.8% per quarter
Revenue Fall
![]()
Revenue is down for the last 2 quarters, 825.41M → 776.13M (in $), with an average decrease of 6.0% per quarter
| Organisation | Biomarin Pharmaceutical Inc. |
| Headquarters | 770 Lindaro Street, San Rafael, CA, United States, 94901 |
| Industry | Health Technology |
| CEO | Mr. Alexander Hardy |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. George Eric Davis J.D. | Executive VP, Chief Legal Officer, General Counsel & Secretary |
Ms. Cristin Hubbard | Executive VP & Chief Commercial Officer |
Dr. C. Greg Guyer Ph.D. | Executive VP & CTO |
Mr. Alexander Hardy | President, CEO & Director |
Dr. Gregory Friberg M.D. | Executive VP and Chief Research & Development Officer |
Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development |
Ms. Amy Wireman | Executive VP & Chief People Officer |
Dr. Ganesh Vedantham Ph.D. | Senior Vice President of Technical Development |
Ms. Marni Kottle | Executive VP & Chief Corporate Affairs Officer |
Mr. Brian R. Mueller CPA | Executive VP of Finance, CFO & Principal Accounting Officer |
Biomarin Pharmaceutical Inc. share price today is $54.74 as on at the close of the market. Biomarin Pharmaceutical Inc. share today touched a day high of $55.3 and a low of $53.67.
Biomarin Pharmaceutical Inc. share touched a 52 week high of $73.51 on and a 52 week low of $50.76 on . Biomarin Pharmaceutical Inc. stock price today i.e. is closed at $54.74,which is 25.53% down from its 52 week high and 7.84% up from its 52 week low.
Biomarin Pharmaceutical Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Biomarin Pharmaceutical Inc. (BMRN) shares with as little as ₹88.7 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.00 in Biomarin Pharmaceutical Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Biomarin Pharmaceutical Inc. share’s latest price of $54.74 as on November 15, 2025 at 2:29 am IST, you will get 0.1827 shares of Biomarin Pharmaceutical Inc.. Learn more about
fractional shares .
Biomarin Pharmaceutical Inc. stock has given -30.06% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?